Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• The patient must be 365 days old or younger at the time of diagnosis.
• The patient must have a newly diagnosed blood cancer called acute lymphoblastic leukemia (ALL) or acute undifferentiated leukemia, where the cancer cells test positive for a protein called CD19.
• Patients with a mixed type of acute leukemia may be eligible, provided the cancer cells test positive for CD19.
• Patients with a specific type of mature B-cell ALL that has a particular gene change called a KMT2A rearrangement may be eligible.
• Prior treatment must have been very limited — only small amounts of certain medicines (hydroxyurea for 72 hours or less, steroids for one week or less, cytarabine for 72 hours or less), at most one dose of vincristine, and at most one intrathecal (spinal) chemotherapy dose.
• A parent or legal guardian must be willing and able to provide written informed consent following all required guidelines.

Who may not be able to join:

• Patients who have received treatments beyond the very limited prior therapy described above.
• Patients with mature B-cell ALL that does not have the KMT2A gene rearrangement.
• Patients whose cancer is a type called AML (acute myelogenous leukemia) or T-cell ALL.
• Patients who have Down syndrome.
• Patients whose parent or legal guardian is unable or unwilling to provide written informed consent.

Important: Always verify eligibility with the trial site directly before applying.